Murley, Chantelle http://orcid.org/0000-0003-4150-4275
Tinghög, Petter http://orcid.org/0000-0001-6138-6427
Teni, Fitsum Sebsibe http://orcid.org/0000-0002-6182-499X
Machado, Alejandra http://orcid.org/0000-0001-8957-661X
Alexanderson, Kristina http://orcid.org/0000-0002-9313-3413
Hillert, Jan http://orcid.org/0000-0002-7386-6732
Karampampa, Korinna http://orcid.org/0000-0002-2578-1865
Friberg, Emilie http://orcid.org/0000-0001-7874-4243
Funding for this research was provided by:
Vetenskapsrådet (2017-00624)
Biogen
Karolinska Institute
Article History
Received: 7 March 2022
Accepted: 7 November 2022
First Online: 23 November 2022
Declarations
:
: CM, AM, FT, and EF were partly funded by an unrestricted research grant from Biogen. KA has received unrestricted researcher-initiated grants from Biogen. EF has received unrestricted researcher-initiated grants from Celgene. PT has previously received salaries partly funded by Biogen and has no conflicts to declare. KK has previously been employed and received salaries from Karolinska Institutet which were partly funded by Biogen, but not for conducting this study and has not received any salary from Karolinska Institutet or Biogen since October 2019. Presently, KK is working full time at Bristol Myers Squibb. JH received honoraria for serving on advisory boards for Biogen and Novartis and speaker’s fees from Biogen, Merck-Serono, Bayer-Schering, Teva, and Sanofi-Aventis. He has served as principal investigator for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis, and Bayer-Schering. JH’s MS research is also funded by the Swedish Research Council.
: The project received ethical approval from the Regional Ethical Review Board in Stockholm, Sweden (reference numbers: 2007/762-31; 2009/23-32; 2009/1917-32; 2010/466-32; 2011/806-32; 2011/1710-32; 2014/236-32; and 2016/1553-32). The study was performed in accordance with the tenants of the Declaration of Helsinki and later amendments. Informed consent from the research participants was not applicable due to the use of pseudonymised data from total population administrative registers and that we do not hold the details revealing the identity of the participants. Individuals with MS included in the Swedish MS Registry provided consent to their neurologist to enter their information into the register for both clinical and research purposes.